#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides an unaudited trading update for the year ended 31 December 2024.   Highlights ·    Revenue up 11.9% to £62.7 million (2023: £56.0 million) ·    EBITDA margin of c.26% (2023: 23.3%) ·    Cash of £44.2 million as at 31 December 2024 (31 December 2023: £37.0 million)…

Continue reading

#HVO hVIVO PLC – Long Term Incentive Plan/ PDMR Notification October 11, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the Company has granted Yamin Khan, the Company’s Chief Executive Officer, and certain senior employees, a Long Term Incentive Plan (“LTIP”).   The awards are intended to reward, incentivise and retain Mr Khan and certain senior employees to deliver sustainable growth for shareholders.   Under the LTIP, Mr Khan has…

Continue reading

#HVO hVIVO PLC – Euronext cancellation August 5, 2024 – Posted in: hVIVO (HVO), Vela Technologies Plc (VELA)

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its intention to cancel its admission (“the Cancellation”) to trading on Euronext Growth.   As hVIVO’s primary operations, along with the majority of its employees and investor base, are in the UK, the Board has decided to consolidate trading of the Company’s stock to its primary…

Continue reading

#VELA investee co. #TRYB Tribe Technology PLC – First autonomous RC drill rig video update July 5, 2024 – Posted in: Vela Technologies Plc (VELA)

Tribe Technology PLC (AIM: TRYB), a disruptive technology-first developer and manufacturer of world-class autonomous mining equipment, is pleased to share a video of its first autonomous reverse circulation drill rig performing final software & function testing prior to shipping.   The Company has made significant progress following the completion of manufacturing of the first TTDS GC 700 drill rig (the “Drill Rig”) and has already reached several milestones towards the shipment of the Drill Rig…

Continue reading

#VELA investee co. #TRYB Tribe Technologies PLC – Unaudited half year results March 28, 2024 – Posted in: Vela Technologies Plc (VELA)

Tribe Technology PLC (AIM: TRYB), a disruptive developer and manufacturer of autonomous mining equipment, announces its unaudited half-year results for the six months ended 31 December 2023 (“H1 2024” or the “period”). H1 2024 Operating Highlights During the period the Company made significant progress in the product development of the first generation autonomous TTDS GC 700 drill rig for delivery to Major Drilling Group International Inc (“Major Drilling”) (“Rig 1”), continued manufacturing its TTDS GC…

Continue reading

#HVO hVIVO PLC – Proposed Secondary Placing of Ordinary Shares February 14, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has been informed by certain Directors of the Company of their intention to sell, in aggregate, not less than 14,000,000 ordinary shares of 0.1 pence each (“Ordinary Shares”) in the capital of Company (the “Placing Shares”), representing approximately 25% of their current shareholding, at a price of 28 pence per Placing…

Continue reading

#HVO hVIVO PLC – Final results April 25, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited results for the 12 months ended 31 December 2022.   Financial highlights ·    Revenue up 30% to £50.7m (2021: £39.0m) ·    EBITDA increased threefold to £9.1m (2021: £2.9m) ·    EBITDA margins of 17.9% (2021: 7.4%), ahead of guidance due…

Continue reading